Neurocrine Biosciences, Inc. (NBIX) Financials
NBIX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2024-03-31 | 3.5 billion | 1.1 billion |
2023-12-31 | 3.3 billion | 1.0 billion |
2023-09-30 | 2.8 billion | 846.1 million |
2023-06-30 | 2.6 billion | 760.1 million |
NBIX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2024-03-31 | 119.1 million | 44.5 million |
2023-12-31 | 118.1 million | 38.1 million |
2023-09-30 | 204.4 million | 47.8 million |
2023-06-30 | 172.8 million | 68.5 million |
NBIX Net Income
No data available :(
NBIX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2024-03-31 | 1.2 billion | - | 252.9 million |
2023-12-31 | 1.0 billion | - | 258.3 million |
2023-09-30 | 1.1 billion | - | 85.9 million |
2023-06-30 | 976.7 million | - | 89.1 million |
NBIX Shares Outstanding
NBIX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2024-03-31 | 11.2 million | 154.1 million | 243.1 million | - |
2023-12-31 | 5.4 million | 137.5 million | 218.9 million | - |
2023-09-30 | 7.6 million | 142.2 million | 204.2 million | - |
2023-06-30 | 6.8 million | 145.8 million | 221.8 million | - |
NBIX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2024-03-31 | 515.3 million | 12.8 million |
2023-12-31 | 515.2 million | 8.5 million |
2023-09-30 | 498.8 million | 11.2 million |
2023-06-30 | 452.7 million | 11.5 million |
NBIX
Price: $143.19
52 week price:
Earnings Per Share: 2.47 USD
P/E Ratio: 53.35
Exchange: NMS
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 490000
Ebitda: 15.0 millionMarket Capitalization: 14.4 billion